The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia

Oncologist

Volumn 5, Issue 4, 2000, Pages 321-328

  Friedmann, A M ^a   Weinstein, H J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Childhood; Pediatric; Prognostic factors; Treatment

Indexed keywords

DEXAMETHASONE; DNA; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 0033857092     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-4-321     Document Type: Article

References (62)

1. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group
2. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01
3. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: Randomized controlled trial from the Children's Cancer Group
4. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia
5. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
6. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis
7. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: A Pediatric Oncology Group study
8. Biology and treatment of acute lymphoblastic leukemia
9. Ethnicity and survival following childhood acute lymphoblastic leukemia (ALL): Follow-up of the Children's Cancer Group (CCG) cohort
10. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic lymphoma
11. Immunologically defined subclasses of acute lymphoblastic leukemia in children: Their relationship to presentation features and prognosis
12. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study
13. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings and outcome: A collaborative study of the Groupe Francais de Cytogenetique Hematologique
14. Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocol. Results of treatment
15. National cancer clinical trials: Children have equal access; adolescents do not
16. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia
17. Cell surface antigens: Prognostic implications in childhood acute lymphoblastic leukemia
18. Prevention and treatment of meningeal leukemia in children
19. Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia
20. Pretreatment testicular biopsy in childhood acute lymphocytic leukemia
21. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study
22. Clinical and biological features predict poor prognosis in acute lymphoid leukemias in children and adolescents: A Pediatric Oncology Group review
23. Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis
24. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
25. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Children's Cancer Group
26. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group
27. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: A Pediatric Oncology Group study
28. +) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediciton of a favorable treatment outcome
29. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group Study
30. Stratification by stepwise regression, corresponding analysis, and recursive partitioning: A comparison of three models of survival analysis with covariates
31. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphocytic leukemia
32. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: A Pediatric Oncology Group study
33. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
34. Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia
35. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line
36. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: Results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia
37. Molecular genetics of childhood cancer: Implications for pathogenesis, diagnosis, and treatment
38. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
39. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia
40. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia
41. Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia
42. Current status of cytogenetic research in childhood acute lymphoblastic leukemia
43. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): A Pediatric Oncology Group study
44. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19)
45. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: A report from the Children's Cancer Group
46. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome
47. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study
48. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age
49. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
50. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
51. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
52. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
53. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children
54. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia
55. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect
56. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children
57. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
58. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: Differences in outcome are poorly explained by the most significant prognostic variables
59. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
60. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency
61. Results of the Dana-Farber Cancer Institute Consortium Protocol 91-01 for children with acute lymphoblastic leukemia
62. Dexamethasone decreases central nervous system relapse and improves event-free survival in lower risk acute lymphoblastic leukemia